Healthcare Professionals > Oncotype DX Breast Recurrence Score

The Oncotype DX Breast Recurrence® test provides significant value in clinical practice

For node-positive, early-stage breast cancer patients

The Oncotype DX Breast Recurrence Score test is predictive of chemotherapy benefit for your postmenopausal patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer as demonstrated by SWOG-88141. Data from SWOG-8814 and RxPONDER show that a substantial proportion of these patients may be spared chemotherapy1-3.

Postmenopausal vs Premenopausal graphic

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy1-3

A large proportion4,5 of HR+, HER2-, node-positive postmenopausal patients receive chemotherapy as node-positive disease is considered high clinical risk due to worse prognosis6. Average chemotherapy treatment rates without genomic testing are in the range of 70% for this patient population4,5. RxPONDER demonstrated that many of these patients may be overtreated, assuming that chemotherapy was considered because of their high clinical risk2,3, and the Oncotype DX test can help make informed treatment decisions.



Another recent study published in 2023 shows that the Oncotype DX test increases confidence and concordance among oncologists in adjuvant chemotherapy recommendations for early-stage breast cancer  

The study concludes that

  • the Oncotype DX® test significantly reduces uncertainty related to therapeutic decisions 
  • the Oncotype DX® test reduces discordance in treatment choice among oncologists



In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify a significant proportion of node-positive patients (with up to 3 positive nodes) who may not benefit from the addition of chemotherapy1-3​.


The Oncotype DX Breast Recurrence Score* test should be used for:

  • All patients for whom chemotherapy may be spared1-3
  • All patients for whom chemotherapy may be life-saving1-3
*For early stage, HR+, HER2- patients with up to 3 nodes involved


Contact Us